Study: Alogliptin does not raise heart risk in diabetes

10/3/2013 |

The diabetes drug alogliptin did not appear to increase the odds of heart attack, stroke or cardiac death compared with placebo in type 2 diabetes patients with cardiovascular problems, a study in The New England Journal of Medicine revealed. Data on 5,380 patients showed 11.3% of those in the alogliptin arm died from heart problems or suffered a heart attack or stroke, compared with 11.8% of those who took a placebo.

View Full Article in:

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Director, Biostatistics
Edwards Lifesciences
Irvine, CA
Diagnostic Technician
Marlborough, MA
Test Technician
Marlborough, MA
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC
Senior Paralegal - Research & Development, and Medical
Boehringer Ingelheim
Ridgefield, CT